To determine if the synergy observed in HER2+ breast cancer models is specific to neratinib and dasatinib, we wished to evaluate the effectiveness of (1) different HER2-targeted TKIs in combination with dasatinib and (2) other Src/c-abl inhibitors in combination with HER2-targeted TKIs. Here, SRC is linked to breast cancer.